Anti-diabetic properties of the Canadian lowbush blueberry Vaccinium angustifolium Ait.
Incidence of type II diabetes is rapidly increasing worldwide. In order to identify complementary or alternative approaches to existing medications, we studied anti-diabetic properties of Vaccinium angustifolium Ait., a natural health product recommended for diabetes treatment in Canada. Ethanol extracts of root, stem, leaf, and fruit were tested at 12.5 microg/ml for anti-diabetic activity in peripheral tissues and pancreatic beta cells using a variety of cell-based bioassays. Specifically, we assessed: (1) deoxyglucose uptake in differentiated C2C12 muscle cells and 3T3-L1 adipocytes; (2) glucose-stimulated insulin secretion (GSIS) in beta TC-tet pancreatic beta cells; (3) beta cell proliferation in beta TC-tet cells; (4) lipid accumulation in differentiating 3T3-L1 cells; (5) protection against glucose toxicity in PC12 cells. Root, stem, and leaf extracts significantly enhanced glucose transport in C2C12 cells by 15-25% in presence and absence of insulin after 20 h of incubation; no enhancement resulted from a 1 h exposure. In 3T3 cells, only the root and stem extracts enhanced uptake, and this effect was greater after 1 h than after 20 h; uptake was increased by up to 75% in absence of insulin. GSIS was potentiated by a small amount in growth-arrested beta TC-tet cells incubated overnight with leaf or stem extract. However, fruit extracts were found to increase 3H-thymidine incorporation in replicating beta TC-tet cells by 2.8-fold. Lipid accumulation in differentiating 3T3-L1 cells was accelerated by root, stem, and leaf extracts by as much as 6.5-fold by the end of a 6-day period. Stem, leaf, and fruit extracts reduced apoptosis by 20-33% in PC12 cells exposed to elevated glucose for 96 h. These results demonstrate that V. angustifolium contains active principles with insulin-like and glitazone-like properties, while conferring protection against glucose toxicity. Enhancement of proliferation in beta cells may represent another potential anti-diabetic property. Extracts of the Canadian blueberry thus show promise for use as a complementary anti-diabetic therapy.
Martineau
Louis C
LC
Department of Pharmacology and Membrane Protein Study Group, Université de Montréal, and Montreal Diabetes Research Center, Centre de recherche du Centre Hospitalier de l'Université de Montréal, QC, Canada.
Couture
Audrey
A
Spoor
Danielle
D
Benhaddou-Andaloussi
Ali
A
Harris
Cory
C
Meddah
Bouchra
B
Leduc
Charles
C
Burt
Andrew
A
Vuong
Tri
T
Mai Le
Phuong
P
Prentki
Marc
M
Bennett
Steffany A
SA
Arnason
John T
JT
Haddad
Pierre S
PS
D016475:3T3 Cells; D000818:Animals; D029798:Blueberry Plants / Q000737:chemistry*; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D019610:Cytoprotection / Q000187:drug effects; D003847:Deoxyglucose / Q000378:metabolism; D005947:Glucose / Q000378:metabolism / Q000633:toxicity; D007004:Hypoglycemic Agents / Q000032:analysis / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects; D051379:Mice; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology
D007004:Hypoglycemic Agents; D007328:Insulin; D010936:Plant Extracts; D003847:Deoxyglucose; D005947:Glucose